Analysts Boost BridgeBio Pharma’s Price Target to $74.37

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have received a consensus rating of “Moderate Buy” from twenty-one analysts currently covering the company, according to MarketBeat Ratings. While one analyst recommends selling the stock, the overwhelming majority, twenty analysts, advocate for buying. The average price target set by these brokers for the next twelve months stands at $74.37.

Several financial institutions have recently provided updates on BridgeBio Pharma’s stock. On October 30, 2023, the Goldman Sachs Group raised its price objective for the company from $55.00 to $100.00 and maintained a “buy” rating. Following suit, Truist Financial reiterated its “buy” rating and increased its target price from $66.00 to $80.00. HC Wainwright also reaffirmed a “buy” rating with a price target of $90.00, while Raymond James Financial adjusted its target price up from $69.00 to $71.00.

Company Earnings and Performance

BridgeBio Pharma’s latest earnings report, released on October 29, 2023, revealed a loss of ($0.95) per share for the quarter. This outcome fell short of analysts’ consensus estimate of ($0.88) by $0.07. Despite the loss, the company reported revenue of $120.70 million, exceeding forecasts of $107.71 million. This represents a significant increase of 4318% compared to the same quarter in the previous year when earnings per share were ($0.86). Analysts project that BridgeBio Pharma will post an earnings per share of ($3.67) for the current fiscal year.

Insider Trading Activity

In recent news regarding insider trading, Director Hannah Valantine sold 25,484 shares of BridgeBio Pharma on November 12, 2023, at an average price of $66.07, totaling approximately $1.68 million. Following this transaction, Valantine retained 7,465 shares valued at around $493,212.55, marking a 77.34% reduction in her ownership.

Additionally, Chief Financial Officer Thomas Trimarchi sold 16,934 shares on November 17, 2023, at an average price of $66.46, amounting to about $1.13 million. After this sale, Trimarchi holds 382,830 shares, worth approximately $25.44 million, representing a 4.24% decrease in his stake. Over the last quarter, insiders have sold a total of 629,204 shares valued at $39.42 million, with insiders currently owning 18.20% of the company’s stock.

Institutional Investor Movements

A number of institutional investors have adjusted their positions in BridgeBio Pharma recently. Vanguard Group Inc. increased its stake by 2.1% in the third quarter, now holding 16,832,059 shares worth approximately $874.26 million. Farallon Capital Management LLC raised its holdings by 3.7%, now owning 8,192,000 shares valued at about $425.49 million. Furthermore, Aisling Capital Management LP increased its position by 0.4% and now holds 6,089,611 shares worth $316.29 million.

Invesco Ltd. significantly raised its stake by 40.3%, acquiring 3,928,657 shares valued at $204.05 million. Geode Capital Management LLC also boosted its holdings by 5.1%, now owning 3,681,580 shares worth approximately $158.99 million. Overall, institutional investors control 99.85% of BridgeBio Pharma’s stock.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on developing transformative medicines to address genetic diseases and cancers. Its pipeline includes AG10, a near-complete TTR stabilizer currently in Phase 3 trials for treating transthyretin amyloid cardiomyopathy; a low-dose version of infigratinib, aimed at children with achondroplasia; and BBP-631, a gene transfer product candidate in Phase 1/2 trials for congenital adrenal hyperplasia driven by 21-hydroxylase deficiency.

As analysts continue to evaluate BridgeBio Pharma’s performance and growth potential, the company’s recent stock activity and insider transactions will likely influence investor sentiment moving forward.